Notice for ruxolitinib (as phosphate) (Novartis Pharmaceuticals Australia Pty Ltd)
Active ingredients
ruxolitinib (as phosphate)
Date of review outcome
Lapse date
Type
Priority review
Indication
Jakavi is indicated for the treatment of patients with Graft versus Host Disease (GvHD) 12 years and older who have inadequate response to corticosteroids or other systemic therapies
Therapeutic area
Immunology